{
     "PMID": "7566497",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "19951114",
     "LR": "20161123",
     "IS": "0028-3908 (Print) 0028-3908 (Linking)",
     "VI": "34",
     "IP": "6",
     "DP": "1995 Jun",
     "TI": "Studies on the role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release--I. BMY7378 and prazosin.",
     "PG": "615-20",
     "AB": "UNLABELLED: The present study utilized in vivo microdialysis to investigate the importance of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the decreased 5-HT release obtained following administration of the mixed 5-HT1A autoreceptor partial agonist/alpha 1-adrenoceptor antagonist BMY7378, the selective 5-HT1A receptor agonist 8-OH-DPAT and the alpha 1-adrenoceptor antagonist prazosin. BMY7378 (0.25 mg/kg, s.c.), 8-OH-DPAT (0.025 mg/kg, s.c.) and prazosin (0.1-1.0 mg/kg, s.c.) all suppressed ventral hippocampal 5-HT efflux. The BMY7378- and 8-OH-DPAT-induced inhibition of 5-HT release were reversed by a 40 min pre-treatment with either (+/-)pindolol (8 mg/kg, s.c.) or WAY-100635 (0.3 mg/kg, s.c.), to block 5-HT1A autoreceptors. Neitehr of these antagonists altered the prazosin-induced (0.3 mg/kg, s.c.) 5-HT disease. THE RESULTS: (i) confirm that both an alpha 1-adrenoceptor antagonist (prazosin) and 5-HT1A autoreceptor stimulants (BMY7378 and 8-OH-DPAT) may reduce cerebral 5-HT release; (ii) support that the BMY7378-induced decrease in 5-HT release results from 5-HT1A autoreceptor agonism, rather than alpha 1-adrenoceptor blockade; and (iii) argue against \"physiological\" antagonism (i.e. via blockade of beta-adrenoceptors, 5-HT1B receptors or some other mechanism) as an explanation for the reversal by pindolol of 5-HT1A autoreceptor agonist-induced suppression of 5-HT release. These data support the usefulness of pindolol, as well as the more specific compound WAY-100635, to block 5-HT1A autoreceptors.",
     "FAU": [
          "Hjorth, S",
          "Bengtsson, H J",
          "Milano, S",
          "Lundberg, J F",
          "Sharp, T"
     ],
     "AU": [
          "Hjorth S",
          "Bengtsson HJ",
          "Milano S",
          "Lundberg JF",
          "Sharp T"
     ],
     "AD": "Department of Pharmacology, University of Goteborg, Sweden.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0 (Piperazines)",
          "0 (Receptors, Adrenergic, alpha-1)",
          "0 (Receptors, Serotonin)",
          "333DO1RDJY (Serotonin)",
          "BJ4HF6IU1D (Pindolol)",
          "KC07KV8T5O (BMY 7378)",
          "XM03YJ541D (Prazosin)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Dose-Response Relationship, Drug",
          "Hippocampus/*drug effects",
          "Male",
          "Microdialysis",
          "Pindolol/pharmacology",
          "Piperazines/*pharmacology",
          "Prazosin/*pharmacology",
          "Rats",
          "Rats, Sprague-Dawley",
          "Receptors, Adrenergic, alpha-1/*drug effects/*physiology",
          "Receptors, Serotonin/*drug effects/*physiology",
          "Serotonin/*secretion",
          "Time Factors"
     ],
     "EDAT": "1995/06/01 00:00",
     "MHDA": "1995/06/01 00:01",
     "CRDT": [
          "1995/06/01 00:00"
     ],
     "PHST": [
          "1995/06/01 00:00 [pubmed]",
          "1995/06/01 00:01 [medline]",
          "1995/06/01 00:00 [entrez]"
     ],
     "AID": [
          "0028390895000388 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 1995 Jun;34(6):615-20.",
     "term": "hippocampus"
}